MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
about
CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-cateninTargeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.Casein kinases as potential therapeutic targets.Investigational drugs for head and neck cancer.Prognostic value from integrative analysis of transcription factors c-Jun and Fra-1 in oral squamous cell carcinoma: a multicenter cohort study.TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.Cancer-type dependent expression of CK2 transcripts.CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent MechanismEpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers
P2860
Q36263671-351831E7-0717-4F3B-BE1B-22B4BF59A2D9Q37619722-EE19646B-1A2F-4716-8D0F-9C30B5D80BFAQ37731326-40BCA9C6-C4B0-4F17-A7E5-DB6010219976Q38632634-04CAA36F-5E61-4114-A044-B1B9BCAEEF4AQ38800788-B61A0CA6-C1A2-45A4-A698-CA50DD2839B5Q40090069-6BCA4F04-05D5-4C54-9826-3274FF5B2D78Q41617837-10CB401A-E4B4-48C6-B141-054ABC61DF8EQ45790068-C00F9F06-A9D1-4FF5-8B55-363A1C0D9C33Q45997277-8F2E8364-94A5-40A6-B4ED-B5D2686BCA6FQ47114281-C1F98A8E-FAC6-447F-B676-D8CC50A19FDEQ58710589-2EE164E8-632B-4936-AB8E-A2DF585EC483Q59127611-D2381487-CA16-4446-B1F2-16025A69E423
P2860
MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@ast
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@en
type
label
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@ast
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@en
prefLabel
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@ast
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@en
P2093
P2860
P356
P1476
MEK inhibitor PD-0325901 overc ...... ivity in head and neck cancer.
@en
P2093
Carter VanWaes
Jay Friedman
Jiawei Han
Vishnu Kannabiran
Yansong Bian
Zhong Chen
P2860
P304
P356
10.7150/IJBS.10745
P407
P50
P577
2015-02-23T00:00:00Z